“The decrease potential is even higher than our forecast. It can be between 0 and -1.5%,” Craciun told ZF Pharma & Health Summit.
Cegedim’s basic scenario for this year indicates a 0.3% decrease, given that local drug sales returned to a 6% growth in the second quarter of the year (5% in euros), reaching RON3 billion (EUR680 million), after three consecutive quarters on a downward trend.
“For 2015, it depends on several aspects, but one of the main aspects is the final version of the list with reimbursed drugs. If it is generous, the market might return to growth, if it is less generous, like I expect, the market might rather fall,” Craciun concluded.